A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration - Concepedia

Concepedia

Publication | Open Access

A Randomized, Double-Masked, Multicenter Trial of Topical Acrizanib (LHA510), a Tyrosine Kinase VEGF-Receptor Inhibitor, in Treatment-Experienced Subjects With Neovascular Age-Related Macular Degeneration

DOI Full Paper Access

19

Citations

14

References

2022

Year

Stephen Poor, Georges Weissgerber, Christopher M. Adams, Harit Bhatt, David J. Browning, James E. Chastain, Thomas A. Ciulla, Michael Ferriere, Kinfemichael Gedif, Louis C. Glazer,

American Journal of Ophthalmology

Abstract

In spite of extensive optimization for topical efficacy, LHA510 failed to demonstrate clinical efficacy.

References

	Year	Citations

Page 1